NasdaqGS:ORICBiotechs
Do ORIC Pharmaceuticals’ Widening Losses But Lower Per-Share Losses Reveal a Strategic Trade-Off for ORIC?
In the past quarter, ORIC Pharmaceuticals, Inc. reported a second-quarter 2026 net loss of US$41.49 million, up from US$36.36 million a year earlier, while basic and diluted loss per share from continuing operations improved to US$0.38 from US$0.47.
For the first half of 2026, net loss widened to US$77.26 million compared with US$66.38 million a year ago, yet basic and diluted loss per share narrowed to US$0.72 from US$0.89, highlighting the impact of a larger share count on per-share...